Novo Nordisk submitted a BLA to the Food and Drug Administration for denecimig for the treatment of hemophilia A in September 2025.
About one-third of children and adolescents use dietary supplements in the US, according to a study published online April 24 in Pediatrics Open Science. Brandy ...
Data from ARTISTRY trials demonstrated that switching to a single-tablet regimen of bictegravir and lenacapavir is ...
Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.
MPR spoke with Dr Daniela Carvalho, an investigator in the CHORD trial, the results form which formed the basis for the approval of Otarmeni.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results